Cancer Research Meeting Calendar  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 54, 5154-5159, October 1, 1994]
© 1994 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kihara, A.
Right arrow Articles by Pastan, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kihara, A.
Right arrow Articles by Pastan, I.

Small Chimeric Toxins Containing Only Transforming Growth Factor {alpha} and Domain III of Pseudomonas Exotoxin with Good Antitumor Activity in Mice

Ako Kihara and Ira Pastan1

Laboratory of Molecular Biology, Division of Cancer Biology, Diagnosis, and Centers, National Cancer Institute, NIH, Bethesda, Maryland 20892

Chimeric toxins composed of transforming growth factor {alpha} (TGF{alpha}) fused to mutant forms of Pseudomonas exotoxin (PE) bind to the epidermal growth factor receptor and kill cells bearing epidermal growth factor receptors. Initially, the binding domain (Ia; amino acids 1–252) of PE was deleted and replaced with TGF{alpha} to make TGF{alpha}-PE40 in which TGF{alpha} is fused to domains II, Ib, and III of PE (amino acids 253–613). That drug is currently undergoing clinical study for the intravesical therapy of bladder cancer. To generate smaller molecules that would have increased tumor penetration, several deletion mutants were constructed. In one of these, TGF{alpha} was inserted near the carboxyl terminus of PE, and residues in domains II and Ib of PE (amino acids 253–279 and 365–380) were deleted so that the chimeric toxin did not need to be cleaved by an intracellular protease to be activated (Theuer et al., J. Biol. Chem., 267: 16872–16877, 1992). We have now constructed chimeric toxins which contain only domain III, yet still exhibit high cytotoxic activity on epidermal growth factor receptor-containing cells and produce substantial tumor regressions in mice bearing a human xenograft. The high cytotoxic activity of these severely truncated toxins provides new insights on the proposed functions of domains II and III of PE.

1 To whom requests for reprints should be addressed, at Laboratory of Molecular Biology, National Cancer Institute, NIH, 9000 Rockville Pike, Building 37, Room 4E16, Bethesda, Maryland 20892

Received 5/ 4/94. Accepted 8/ 4/94.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
T. F. Liu, P. D. Hall, K. A. Cohen, M. C. Willingham, J. Cai, A. Thorburn, and A. E. Frankel
Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice
Clin. Cancer Res., January 1, 2005; 11(1): 329 - 334.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.